A and S Drugs

Belkins
A and S Drugs is a family-owned business which has been part of the Pipestone, MN, community since the day it first opened its doors for customers in October 1951. In over 60 years of operation, your healthcare needs have always been our top priority. Our highly qualified staff is committed to providing every customer with the very best in pharmacy service. Not only do we deal with prescriptions, but we also offer you a personal and confidential pharmacy care experience. We understand that you lead busy lives and need support when you are unwell, with fast, reliable, and quality service. And this is exactly what we’re here for.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CORRECTING AND REPLACING CIRCLE PHARMA RAISES $45 MILLION IN SERIES B FINANCING

Business Wire | March 17, 2020

news image

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing. The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round – ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund – joined the financing. In conjunction with the financing, Peter Svennilson, founder and managing partner of The Column Gro...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

FOLLOWING LAB TEST, EAGLE PHARMA LOOKS TO TEST MH DRUG RYANODEX AGAINST COVID-19

BioSpace | April 16, 2020

news image

In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic. Now the company hopes to launch a clinical trial testing the efficacy of the drug in patients. In the in vitro tests, Ryanodex demonstrated antiviral activity and a lack of cytotoxicity. Two days after dosing, the in vitro results showed an absence of cytopathic effects in the infected cells. This ...

Read More

PHARMA TECH

BENCHSCI NAMED A DELOITTE TECHNOLOGY FAST 50™ COMPANY AS IMPACT ON DRUG DISCOVERY GROWS

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

news image

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “ Read More

Business Wire | March 17, 2020

news image

CORRECTING AND REPLACING CIRCLE PHARMA RAISES $45 MILLION IN SERIES B FINANCING

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing. The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round – ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund – joined the financing. In conjunction with the financing, Peter Svennilson, founder and managing partner of The Column Gro...

Read More

Pharmacy Business | January 14, 2020

news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

BioSpace | April 16, 2020

news image

FOLLOWING LAB TEST, EAGLE PHARMA LOOKS TO TEST MH DRUG RYANODEX AGAINST COVID-19

In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic. Now the company hopes to launch a clinical trial testing the efficacy of the drug in patients. In the in vitro tests, Ryanodex demonstrated antiviral activity and a lack of cytotoxicity. Two days after dosing, the in vitro results showed an absence of cytopathic effects in the infected cells. This ...

Read More

PHARMA TECH

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

news image

BENCHSCI NAMED A DELOITTE TECHNOLOGY FAST 50™ COMPANY AS IMPACT ON DRUG DISCOVERY GROWS

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “ Read More